Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
38.24
-0.74 (-1.90%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Celldex Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $59.07. The average 1-year stock price forecast is 54.47% higher than the current stock price, while the lowest is $38 (-0.63%) and the highest is $100 (+161.51%).
Price Target: $59.07 (+54.47%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 13 | 13 | 13 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 16 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $46 → $50 | Buy | Reiterates | $46 → $50 | +30.75% | Sep 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $60 | Buy | Maintains | $60 | +56.90% | Aug 7, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $68 | Buy | Maintains | $68 | +77.82% | Aug 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $61 | Buy | Reiterates | $61 | +59.52% | Aug 7, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $56 | Buy | Maintains | $56 | +46.44% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
2.03M
from 1.55M
Increased by 31.47%
Revenue Next Year
10.71M
from 2.03M
Increased by 427.08%
EPS This Year
-4.12
from -3.90
EPS Next Year
-4.23
from -4.12
EPS and Forward PE are based on non-GAAP adjusted numbers.